BPMC - Blueprint Medicines Corp

QQQ $ 440.32 $ 0.07 (0.02 %)

DIA $ 388.70 $ 0.29 (0.07 %)

SPY $ 517.26 $ 0.57 (0.11 %)

TLT $ 90.79 $ 0.55 (0.61 %)

GLD $ 214.23 $ -0.99 (-0.46 %)

Previous Close

$ 108.55

Open

$ 105.90

Bid

$ 0.00 x 0

Ask

$ 108.74 x 200

Day's Range

$ 104.47 - $ 109.41

52 Week Range

$ 43.89 - $ 110.93

Volume

745,036

Average Volume

Market Cap

6.93B

Beta (5Y Monthly)

$ 1.08

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-02-2024	03-31-2024	10-Q
2	02-15-2024	12-31-2023	10-K
3	10-26-2023	09-30-2023	10-Q
4	08-02-2023	06-30-2023	10-Q
5	05-04-2023	03-31-2023	10-Q
6	02-16-2023	12-31-2022	10-K
7	11-01-2022	09-30-2022	10-Q
8	08-02-2022	06-30-2022	10-Q
9	05-03-2022	03-31-2022	10-Q
10	02-17-2022	12-31-2021	10-K
11	10-28-2021	09-30-2021	10-Q
12	07-29-2021	06-30-2021	10-Q
13	04-29-2021	03-31-2021	10-Q
14	02-17-2021	12-31-2020	10-K
15	10-29-2020	09-30-2020	10-Q
16	07-31-2020	06-30-2020	10-Q
17	05-06-2020	03-31-2020	10-Q
18	02-13-2020	12-31-2019	10-K
19	11-05-2019	09-30-2019	10-Q
20	08-01-2019	06-30-2019	10-Q
21	05-09-2019	03-31-2019	10-Q
22	02-26-2019	12-31-2018	10-K
23	10-30-2018	09-30-2018	10-Q
24	08-01-2018	06-30-2018	10-Q
25	05-02-2018	03-31-2018	10-Q
26	02-21-2018	12-31-2017	10-K
27	10-31-2017	09-30-2017	10-Q
28	08-02-2017	06-30-2017	10-Q
29	05-03-2017	03-31-2017	10-Q
30	03-09-2017	12-31-2016	10-K
31	11-10-2016	09-30-2016	10-Q
32	08-09-2016	06-30-2016	10-Q
33	05-10-2016	03-31-2016	10-Q
34	03-11-2016	12-31-2015	10-K
35	11-09-2015	09-30-2015	10-Q
36	08-10-2015	06-30-2015	10-Q
37	06-11-2015	03-31-2015	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Leerink Partners Upgrades Blueprint Medici...
05/06/2024 17:47:46

Leerink Partners analyst Andrew Berens upgrades Blueprint Medicines (NASDAQ:BPMC) from Underperform to Market Perform and ra...

Goldman Sachs Maintains Buy on Blueprint M...
05/06/2024 15:17:15

Goldman Sachs analyst Terence Flynn maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and raises the price target from ...

Citigroup Maintains Sell on Blueprint Medi...
05/03/2024 21:55:28

Citigroup analyst David Lebowitz maintains Blueprint Medicines (NASDAQ:BPMC) with a Sell and raises the price target from $6...

HC Wainwright & Co. Maintains Buy on Bluep...
05/03/2024 20:14:49

HC Wainwright & Co. analyst Andrew Fein maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and raises the price targ...

JMP Securities Maintains Market Outperform...
05/03/2024 19:02:00

JMP Securities analyst Reni Benjamin maintains Blueprint Medicines (NASDAQ:BPMC) with a Market Outperform and raises the pri...

Barclays Maintains Equal-Weight on Bluepri...
05/03/2024 14:21:12

Barclays analyst Peter Lawson maintains Blueprint Medicines (NASDAQ:BPMC) with a Equal-Weight and raises the price target fr...

Piper Sandler Maintains Neutral on Bluepri...
05/03/2024 13:44:51

Piper Sandler analyst Christopher Raymond maintains Blueprint Medicines (NASDAQ:BPMC) with a Neutral and raises the price ta...

Needham Maintains Buy on Blueprint Medicin...
05/03/2024 09:50:39

Needham analyst Ami Fadia maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and raises the price target from $97 to $130.

C.H. Robinson Worldwide Posts Upbeat Resul...
05/02/2024 14:28:29

Needham Reiterates Buy on Blueprint Medici...
05/02/2024 11:54:23

Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:BPMC) with a Buy and maintains $97 price target.

Blueprint Medicines Corp Expects 2024 Glob...
05/02/2024 11:04:47

2024 Financial Guidance Blueprint Medicines now anticipates approximately $390 million to $410 million in global AYVAKIT net p...

Blueprint Medicines Q1 2024 GAAP EPS $1.40...
05/02/2024 11:01:50

Blueprint Medicines (NASDAQ:BPMC) reported quarterly earnings of $1.40 per share which beat the analyst consensus estimate of $...

12-health-care-stocks-moving-in-wednesdays-after-market-session

12 Health Care Stocks Moving In Wednesday'...
05/01/2024 20:31:24

Stifel Maintains Buy on Blueprint Medicine...
04/26/2024 15:12:56

Stifel analyst Bradley Canino maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and raises the price target from $120 t...

Wedbush Reiterates Outperform on Blueprint...
04/26/2024 14:33:43

Wedbush analyst David Nierengarten reiterates Blueprint Medicines (NASDAQ:BPMC) with a Outperform and maintains $110 price t...

The Analyst Verdict: Blueprint Medicines I...
04/26/2024 12:00:39

HC Wainwright & Co. Reiterates Buy on Blue...
04/26/2024 10:57:16

HC Wainwright & Co. analyst Andrew Fein reiterates Blueprint Medicines (NASDAQ:BPMC) with a Buy and maintains $125 price...

Needham Reiterates Buy on Blueprint Medici...
04/26/2024 09:35:18

Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:BPMC) with a Buy and maintains $97 price target.

Decoding 6 Analyst Evaluations For Bluepri...
04/10/2024 19:00:34

JMP Securities Reiterates Market Outperfor...
04/10/2024 15:02:07

JMP Securities analyst Reni Benjamin reiterates Blueprint Medicines (NASDAQ:BPMC) with a Market Outperform and maintains $11...